Exlinkibart

{
  "id": "MLC-T-ONC-013485",
  "term": "Exlinkibart",
  "field": "Oncology and biomedicine",
  "definition": "A humanized agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, exlinkibart targets and binds to CD137, thereby activating CD137 expressed on avariety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.",
  "synonyms": [
    "anti-4-1BB agonistic monoclonal antibody LVGN6051",
    "anti-CD137 agonist monoclonal antibody LVGN6051",
    "anti-CD137 agonistic monoclonal antibody LVGN6051",
    "anti-CD137 monoclona antibody LVGN6051",
    "anti-CD137 monoclonal antibody LVGN6051"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/exlinkibart/"
}